Accession Therapeutics
June 16, 2025
Company Presentation
Oncology
Creating the ideal immunotherapy which provides potent tumour-selective delivery and tumour-selective killing ability through IV delivery. Lead program entering the clinic in 2025.
.png)
Company HQ City:
Oxford
Company HQ State:
Oxfordshire
Company HQ Country:
United Kingdom
Year Founded:
2021
Lead Product in Development:
TROCEPT-01 incorporates an immune checkpoint inhibitor and is expected to enter Phase 1 in Q1 2025 for treatment of solid tumours. The CTA was filed in the UK in late 2024.
CEO
Bent Jakobsen, CEO
Year Founded
2021
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
Start of Phase 1 in Q1 2025
What is your next catalyst (value inflection) update?
Q1 2025
Website
www.accessiontherapeutics.com
Primary Speaker
)
)
)
)
){kind=logo}
)
){kind=logo}
)
){kind=logo}